Isabelle Tabah-Fisch, MD, a medical oncologist who contributed greatly to drug development, died August 28, 2020, at age 64.
Tabah-Fisch became a certified Doctor in Medicine in 1985 through the Paris Descartes University. She was board certified in clinical hematology, bacteriology and virology, internal medicine, and clinical oncology.
Tabah-Fisch devoted much of her career to the development of anticancer therapeutics. Her research contributed to the development of oxaliplatin (Eloxatin), docetaxel (Taxotere), cabazitaxel (Jevtana), aflibercept (Zaltrap), and seribantumab.
Tabah-Fisch began her corporate career at Schering-Plough in France, where she was the oncology/hematology medical director. She then joined Sanofi, where she held several distinguished positions over nearly two decades. From 2014 to 2016, she worked with biotechnology companies PDC*line Pharma, CarThera, and CleveXel Pharma. In 2016, she joined GamaMabs Pharma, where she became chief medical officer. Under her leadership, GamaMabs developed GM-102 (murlentamab), a monoclonal antibody used to treat gynecological and colorectal cancers.
Tabah-Fisch joined the AACR in 2010, and became a member of the AACR’s Women in Cancer Research. She was also a member of the American Society of Clinical Oncology and the European Society for Medical Oncology.